title: PM00104 (Zalypsis®): a marine derived alkylating agent.
abstract: PM00104 (Zalypsis®) is a synthethic tetrahydroisoquinolone alkaloid, which is structurally similar to many marine organisms. The compound has been proposed as a potential chemotherapeutic agent in the treatment of solid human tumors and hematological malignancies. PM00104 is a DNA binding agent, causing inhibition of the cell cycle and transcription, which can lead to double stranded DNA breaks. After rigorous pre-clinical testing, the drug has been evaluated in a number of phase II clinical trials. This manuscript provides a review of current trials and appraises the efficacy of PM00104 as a future cancer treatment.
authors.affiliation: University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA. bpetek@uw.edu.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Petek
authors.affiliation: Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Avenue East, G-3630, Seattle, WA 98109-1023, USA. rjones@seattlecca.org.
authors.forename: Robin L
authors.initials: RL
authors.lastname: Jones
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D059001:Aquatic Organisms / Q000737:chemistry; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; C500383:PM 00104; D044005:Tetrahydroisoquinolines